DECIDE trial shows Zinbryta (daclizumab high-yield process [HYP]) superior to interferon beta-1a in relapsing remitting MS- Biogen + AbbVie

Full results from the Phase III DECIDE study published this week in the New England Journal of Medicine (NEJM), as well as new post-hoc analyses of Phase III clinical data presented at an international congress, show once-monthly, investigational Zinbryta (daclizumab high-yield process [HYP]) from Biogen + AbbVie, improved results on key measures of multiple sclerosis (MS) disease activity in patients with relapsing-remitting MS (RRMS) compared to interferon beta-1a 30 mcg intramuscular (IM) injection. In the new post-hoc analyses, Zinbryta was shown to increase the percentage of patients achieving no evidence of clinical and MRI disease activity, improve cognitive processing speed and reduce 24-week confirmed disability progression across a broad range of subgroups at two years compared to interferon beta-1a IM. Lead investigators on behalf of Biogen and AbbVie presented these new findings today at the 31st Congress of the European Committee for Treatment and Research in MS (ECTRIMS) in Barcelona, Spain (7-10 October).

More Zinbryta treated patients exhibited no evidence of disease activity (NEDA) (24.6% versus 14.2%; p<0.0001; n=1,841). These results were based on a greater number of Zinbryta patients achieving both clinical NEDA (no relapses and no disability progression) and MRI NEDA (no new/newly enlarging T2-hyperintense lesions and no gadolinium-enhanced lesions).